Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1405 to 1411 of 1411 entries
Sorted by: Best Match Show Resources per page
Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients.

Cancer cell international

Jia B, Dong Z, Wu D, Zhao J, Wu M, An T, Wang Y, Zhuo M, Li J, Wang Y, Zhang J, Zhao X, Li S, Li J, Ma M, Chen C, Yang X, Zhong J, Chen H, Wang J, Chi Y, Zhai X, Cui S, Zhang R, Ma Q, Fang J, Wang Z.
PMID: 33298069
Cancer Cell Int. 2020 Dec 09;20(1):590. doi: 10.1186/s12935-020-01662-5.

BACKGROUND: Although advanced non-squamous non-small cell lung cancer (NSCLC) patients have significantly better survival outcomes after pemetrexed based treatment, a subset of patients still show intrinsic resistance and progress rapidly. Therefore we aimed to use a blood-based protein signature...

Cite
Jia B, Dong Z, Wu D, et al. Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. Cancer Cell Int. 2020;20(1):590doi: 10.1186/s12935-020-01662-5.
Jia, B., Dong, Z., Wu, D., Zhao, J., Wu, M., An, T., Wang, Y., Zhuo, M., Li, J., Wang, Y., Zhang, J., Zhao, X., Li, S., Li, J., Ma, M., Chen, C., Yang, X., Zhong, J., Chen, H., Wang, J., Chi, Y., Zhai, X., Cui, S., Zhang, R., Ma, Q., Fang, J., & Wang, Z. (2020). Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. Cancer cell international, 20(1), 590. https://doi.org/10.1186/s12935-020-01662-5
Jia, Bo, et al. "Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients." Cancer cell international vol. 20,1 (2020): 590. doi: https://doi.org/10.1186/s12935-020-01662-5
Jia B, Dong Z, Wu D, Zhao J, Wu M, An T, Wang Y, Zhuo M, Li J, Wang Y, Zhang J, Zhao X, Li S, Li J, Ma M, Chen C, Yang X, Zhong J, Chen H, Wang J, Chi Y, Zhai X, Cui S, Zhang R, Ma Q, Fang J, Wang Z. Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. Cancer Cell Int. 2020 Dec 09;20(1):590. doi: 10.1186/s12935-020-01662-5. PMID: 33298069; PMCID: PMC7724790.
Copy Download .nbib Format: NLM
Copper-Catalyzed Cyclization of .

Organic letters

Zhu GY, Zhai TY, Li X, Shi CY, Zhu XQ, Ye LW.
PMID: 34609887
Org Lett. 2021 Oct 15;23(20):8067-8071. doi: 10.1021/acs.orglett.1c03092. Epub 2021 Oct 05.

An efficient copper-catalyzed cyclization of

Cite
Zhu GY, Zhai TY, Li X, et al. Copper-Catalyzed Cyclization of . Org Lett. 2021;23(20):8067-8071doi: 10.1021/acs.orglett.1c03092.
Zhu, G. Y., Zhai, T. Y., Li, X., Shi, C. Y., Zhu, X. Q., & Ye, L. W. (2021). Copper-Catalyzed Cyclization of . Organic letters, 23(20), 8067-8071. https://doi.org/10.1021/acs.orglett.1c03092
Zhu, Guang-Yu, et al. "Copper-Catalyzed Cyclization of ." Organic letters vol. 23,20 (2021): 8067-8071. doi: https://doi.org/10.1021/acs.orglett.1c03092
Zhu GY, Zhai TY, Li X, Shi CY, Zhu XQ, Ye LW. Copper-Catalyzed Cyclization of . Org Lett. 2021 Oct 15;23(20):8067-8071. doi: 10.1021/acs.orglett.1c03092. Epub 2021 Oct 05. PMID: 34609887.
Copy Download .nbib Format: NLM
Efficacy and Safety of Epirubicin Combined with Temozolomide for Treatment of Advanced Leiomyosarcoma.

Cancer management and research

Tan H, Zuo L, Ma S, Wang D, Li R, Yang Y, Liu W, Chi Y.
PMID: 34916850
Cancer Manag Res. 2021 Dec 10;13:9075-9083. doi: 10.2147/CMAR.S342213. eCollection 2021.

BACKGROUND: Leiomyosarcoma (LMS) accounts for 24% of all soft tissue sarcomas (STSs) and this STS subtype has high metastatic potential. Previous studies indicated the best median progression-free survival (mPFS) time was 9.2 months and the best overall response rate...

Cite
Tan H, Zuo L, Ma S, et al. Efficacy and Safety of Epirubicin Combined with Temozolomide for Treatment of Advanced Leiomyosarcoma. Cancer Manag Res. 2021;13:9075-9083doi: 10.2147/CMAR.S342213.
Tan, H., Zuo, L., Ma, S., Wang, D., Li, R., Yang, Y., Liu, W., & Chi, Y. (2021). Efficacy and Safety of Epirubicin Combined with Temozolomide for Treatment of Advanced Leiomyosarcoma. Cancer management and research, 139075-9083. https://doi.org/10.2147/CMAR.S342213
Tan, Huijing, et al. "Efficacy and Safety of Epirubicin Combined with Temozolomide for Treatment of Advanced Leiomyosarcoma." Cancer management and research vol. 13 (2021): 9075-9083. doi: https://doi.org/10.2147/CMAR.S342213
Tan H, Zuo L, Ma S, Wang D, Li R, Yang Y, Liu W, Chi Y. Efficacy and Safety of Epirubicin Combined with Temozolomide for Treatment of Advanced Leiomyosarcoma. Cancer Manag Res. 2021 Dec 10;13:9075-9083. doi: 10.2147/CMAR.S342213. eCollection 2021. PMID: 34916850; PMCID: PMC8672029.
Copy Download .nbib Format: NLM
Fast compressive beamforming with a modified fast iterative shrinkage-thresholding algorithm.

The Journal of the Acoustical Society of America

Wang S, Chi C, Jin S, Wang P, Liu J, Huang H.
PMID: 34241101
J Acoust Soc Am. 2021 May;149(5):3437. doi: 10.1121/10.0004997.

Compressive beamforming has been successfully applied to direction-of-arrival estimation with sensor arrays. The results demonstrated that this technique achieves superior performance when compared with traditional high-resolution beamforming methods. The existing compressive beamforming methods use classical iterative optimization algorithms in...

Cite
Wang S, Chi C, Jin S, et al. Fast compressive beamforming with a modified fast iterative shrinkage-thresholding algorithm. J Acoust Soc Am. 2021;149(5):3437doi: 10.1121/10.0004997.
Wang, S., Chi, C., Jin, S., Wang, P., Liu, J., & Huang, H. (2021). Fast compressive beamforming with a modified fast iterative shrinkage-thresholding algorithm. The Journal of the Acoustical Society of America, 149(5), 3437. https://doi.org/10.1121/10.0004997
Wang, Shuo, et al. "Fast compressive beamforming with a modified fast iterative shrinkage-thresholding algorithm." The Journal of the Acoustical Society of America vol. 149,5 (2021): 3437. doi: https://doi.org/10.1121/10.0004997
Wang S, Chi C, Jin S, Wang P, Liu J, Huang H. Fast compressive beamforming with a modified fast iterative shrinkage-thresholding algorithm. J Acoust Soc Am. 2021 May;149(5):3437. doi: 10.1121/10.0004997. PMID: 34241101.
Copy Download .nbib Format: NLM
Taxonomic and phylogenetic studies on two new freshwater Amphileptus species (Ciliophora, Pleurostomatida), from Lake Weishan, northern China.

European journal of protistology

Zhang G, Chi Y, Wang Z, Wang Y, Liu R, Warren A, Zhao Y, Pan H.
PMID: 34922136
Eur J Protistol. 2021 Dec 03;82:125854. doi: 10.1016/j.ejop.2021.125854. Epub 2021 Dec 03.

The morphology and phylogeny of two new species of pleurostomatid ciliates, Amphilepus weishanensis sp. nov. and A. parapleurosigma sp. nov., collected from Lake Weishan in northern China, were studied using live observation, protargol staining and phylogenetic analyses based on...

Cite
Zhang G, Chi Y, Wang Z, et al. Taxonomic and phylogenetic studies on two new freshwater Amphileptus species (Ciliophora, Pleurostomatida), from Lake Weishan, northern China. Eur J Protistol. 2021;82:125854doi: 10.1016/j.ejop.2021.125854.
Zhang, G., Chi, Y., Wang, Z., Wang, Y., Liu, R., Warren, A., Zhao, Y., & Pan, H. (2021). Taxonomic and phylogenetic studies on two new freshwater Amphileptus species (Ciliophora, Pleurostomatida), from Lake Weishan, northern China. European journal of protistology, 82125854. https://doi.org/10.1016/j.ejop.2021.125854
Zhang, Gongaote, et al. "Taxonomic and phylogenetic studies on two new freshwater Amphileptus species (Ciliophora, Pleurostomatida), from Lake Weishan, northern China." European journal of protistology vol. 82 (2021): 125854. doi: https://doi.org/10.1016/j.ejop.2021.125854
Zhang G, Chi Y, Wang Z, Wang Y, Liu R, Warren A, Zhao Y, Pan H. Taxonomic and phylogenetic studies on two new freshwater Amphileptus species (Ciliophora, Pleurostomatida), from Lake Weishan, northern China. Eur J Protistol. 2021 Dec 03;82:125854. doi: 10.1016/j.ejop.2021.125854. Epub 2021 Dec 03. PMID: 34922136.
Copy Download .nbib Format: NLM
An unusual elateroid lineage from mid-Cretaceous Burmese amber (Coleoptera: Elateroidea).

Scientific reports

Li YD, Kundrata R, Packova G, Huang DY, Cai CY.
PMID: 34753998
Sci Rep. 2021 Nov 09;11(1):21985. doi: 10.1038/s41598-021-01398-w.

We here report a new elateroid, Anoeuma lawrencei Li, Kundrata and Cai gen. et sp. nov., from mid-Cretaceous Burmese amber. Though superficially similar to some soft-bodied archostematans, Anoeuma could be firmly placed in the polyphagan superfamily Elateroidea based on...

Cite
Li YD, Kundrata R, Packova G, et al. An unusual elateroid lineage from mid-Cretaceous Burmese amber (Coleoptera: Elateroidea). Sci Rep. 2021;11(1):21985doi: 10.1038/s41598-021-01398-w.
Li, Y. D., Kundrata, R., Packova, G., Huang, D. Y., & Cai, C. Y. (2021). An unusual elateroid lineage from mid-Cretaceous Burmese amber (Coleoptera: Elateroidea). Scientific reports, 11(1), 21985. https://doi.org/10.1038/s41598-021-01398-w
Li, Yan-Da, et al. "An unusual elateroid lineage from mid-Cretaceous Burmese amber (Coleoptera: Elateroidea)." Scientific reports vol. 11,1 (2021): 21985. doi: https://doi.org/10.1038/s41598-021-01398-w
Li YD, Kundrata R, Packova G, Huang DY, Cai CY. An unusual elateroid lineage from mid-Cretaceous Burmese amber (Coleoptera: Elateroidea). Sci Rep. 2021 Nov 09;11(1):21985. doi: 10.1038/s41598-021-01398-w. PMID: 34753998; PMCID: PMC8578672.
Copy Download .nbib Format: NLM
ISLR affects colon cancer progression by regulating the epithelial-mesenchymal transition signaling pathway.

Anti-cancer drugs

Chi C, Liu T, Yang S, Wang B, Han W, Li J.
PMID: 34520435
Anticancer Drugs. 2022 Jan 01;33(1):e670-e679. doi: 10.1097/CAD.0000000000001233.

This study aims to determine the mechanism of ISLR on the progression of colon cancer. TCGA database was used to analyze ISLR expression in colon cancer tumor tissues. QRT-PCR and western blotting were used to detect ISLR expression in...

Cite
Chi C, Liu T, Yang S, et al. ISLR affects colon cancer progression by regulating the epithelial-mesenchymal transition signaling pathway. Anticancer Drugs. 2022;33(1):e670-e679doi: 10.1097/CAD.0000000000001233.
Chi, C., Liu, T., Yang, S., Wang, B., Han, W., & Li, J. (2022). ISLR affects colon cancer progression by regulating the epithelial-mesenchymal transition signaling pathway. Anti-cancer drugs, 33(1), e670-e679. https://doi.org/10.1097/CAD.0000000000001233
Chi, Chunhua, et al. "ISLR affects colon cancer progression by regulating the epithelial-mesenchymal transition signaling pathway." Anti-cancer drugs vol. 33,1 (2022): e670-e679. doi: https://doi.org/10.1097/CAD.0000000000001233
Chi C, Liu T, Yang S, Wang B, Han W, Li J. ISLR affects colon cancer progression by regulating the epithelial-mesenchymal transition signaling pathway. Anticancer Drugs. 2022 Jan 01;33(1):e670-e679. doi: 10.1097/CAD.0000000000001233. PMID: 34520435.
Copy Download .nbib Format: NLM
Showing 1405 to 1411 of 1411 entries